期刊文献+

咪康唑莫米松成膜凝胶的制备及其质量控制 被引量:5

Preparation and Quality Control of Miconazole/Mometason in Skin Membrane Gel
暂未订购
导出
摘要 目的制备咪康唑莫米松皮肤成膜凝胶并建立其质量控制方法。方法选用泊洛沙姆407和泊洛沙姆188为混合基质,冷溶法制备咪康唑莫米松皮肤成膜凝胶,用高效液相色谱法测定咪康唑莫米松含量。结果所制凝胶室温下为液体,涂布皮肤即变为成膜凝胶。咪康唑、莫米松的进样质量浓度分别为10.0~800μg/mL和1.0~80.0μg/mL时与各自峰面积积分值呈良好线性关系,r值分别为0.998 9(n=6)和0.998 1(n=6),咪康唑与莫米松的平均回收率和RSD分别为98.58%,1.46%和97.99%,2.8%(n=6),符合含量测定要求。结论该制剂处方合理,制备工艺简便、质量可控,是一种较为理想的皮肤成膜凝胶。 Objective To prepare miconazole/mometason in skin membrane gel, and to establish a quality control meathod for it. Methods That in skin membrane gel were prepared by cold- solving method with p407 and p188 as mixed base. The content of miconazole and mometason was determined by HPLC- DAD. Results Prepared gels were liguid at room temperature and turned into skin membrane gel at body skin,The linear ranges of miconazole and mometason were in the range of 10.0-800 μg/mL(r=0.998 9), l. 0 - 80. 0 μg/mL( r = 0. 998 1, n = 6) respectively. The average recoveries and RSD of two active ingredients were 98.58% , 1.46% and 98.81%, 2.08% (n = 6). Conclusion The preparation method is reasonable, simple and controllable, and it is an ideal skin membrane gel.
出处 《中国药业》 CAS 2013年第5期53-55,共3页 China Pharmaceuticals
基金 深圳市宝安区科技计划社会公益项目 项目编号:深宝科[2012]24号
关键词 咪康唑 莫米松 皮肤成膜凝胶 制备 质量控制 miconazole mometason skin membrane gel preparation quality contral.
  • 相关文献

参考文献10

二级参考文献33

共引文献27

同被引文献60

  • 1王梦雨,刘祖雄,陈鹰.复方双氯芬酸钠成膜凝胶的制备及质量控制[J].中国药师,2020,23(3):462-467. 被引量:4
  • 2张援,许实波,李向阳,陈颖.不同接受液和动物皮肤对格列美脲体外经皮渗透行为的影响[J].中山大学学报(自然科学版),2004,43(5):86-90. 被引量:23
  • 3孙敬方.动物实验方法学[M].北京:人民卫生出版社,2002.473-474,493.
  • 4Niu G, Du F, Song L, et al. Synthesis and characterization of reactive polox- amer 407s for biomedical applications [J]. J Control Release, 2009, 138 (1):49 -56.
  • 5Bilensoy E, Rouf MA, Vural I, et aL Mucoadhesive, thermosensitive, pro- longed - release vaginal gel for clotrimazole - beta - cyclodextrin complex[J]. AAPS Pharm Sci Tech, 2006,7 (2) : E38.
  • 6Carceles CM, Serrano JM, Marin P, et al. pharmacokinetics of Moxifloxacin in Rabbits after intravenous, subcutaneous and a long- acting poloxamer 407 gel formulation administration [ J ]. J Vet Med, 2006,53:300 - 304.
  • 7Mayol L, Quaglia F, Borzacchiell A, et al. A novel poloxamer/hya- luronic acid in situ forming hydrogel for drug delivery: Rhcolo - gical, mu- coadhesive and in vitro release properties [J]. Eur J pharm Biopharm, 2008,70 ( 1 ) : 199 - 206.
  • 8国家食品药品监督管理局.药物研究技术指导原则:2005[M].北京:中国医药科技出版社,2006:234-250.
  • 9ZGPT5-1.中药、天然药物免疫毒性(过敏性、光变态反应)研究的技术指导原则[S].
  • 10Niu G, Du F, Song L, et al. Synthesis and characterization of reactive polox- amer 407s for biomedical applications [J]. J Control Release,2009,138 (1): 49 - 56.

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部